O
Omeros Corporation (OMER)
NGM – Real vaqt narxi. Valyuta: USD
14.76
+0.40 (2.79%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
14.76
+0.40 (2.79%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Omeros Corporation, klinik bosqichdagi biofarmatsevtika kompaniyasi, immunologik kasalliklarga qarshi kichik molekulalar va oqsil terapiyasini kashf qiladi, ishlab chiqadi va tijoratlashtiradi, shuningdek, o'rtacha ko'rsatkichlarni maqsad qilib oladi. Kompaniyaning asosiy mahsuloti nomzodi Narsoplimab (OMS721/MASP-2) bo'lib, u gemopoetik ildiz hujayralari transplantatsiyasi bilan bog'liq trombotik mikroangiopatiyani (TA-TMA) davolash uchun mo'ljallangan; shuningdek, COVID-19 va o'tkir respirator distress sindromini davolash uchun II bosqich klinik sinovlarida. Kompaniya, shuningdek, mannan-bog'lovchi lektin bilan bog'liq serin proteaza 2 (MASP-2) va lektin yo'li buzilishlari uchun I bosqich klinik sinovlarini yakunlagan OMS1029ni; va giyohvandlik va majburiy buzilishlar, shuningdek, harakat buzilishlari, shuningdek, kokaindan foydalanish buzilishlarini davolash uchun I bosqich klinik sinovlarida bo'lgan OMS527ni ishlab chiqmoqda. Qo'shimcha ravishda, kompaniyaning preklinik rivojlanishdagi mahsulotlari lektin yo'li buzilishlarini davolash uchun yallig'lanishga qarshi oqsil maqsadi bo'lgan MASP-2; muqobil yo'nalishdagi buzilishlar uchun MASP-3 kichik molekulali inhibitorlari; o'tkir miyeloid leykemiyani davolash uchun OncotoX-AML; va ko'p dorilarga chidamli organizmlar uchun Targeted Complement Activating Therapy. Omeros Corporation 1994 yilda tashkil etilgan va shtab-kvartirasi Vashington shtatining Sietl shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Catherine A. Melfi Ph.D. | Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems |
| Dr. George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer & VP of Science |
| Dr. Gregory A. Demopulos M.D. | Co-Founder, Chairman, CEO & President |
| Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder |
| Mr. David J. Borges | VP of Finance, Chief Accounting Officer & Treasurer |
| Mr. David W. Ghesquiere | VP & Chief Business Development Officer |
| Mr. Peter B. Cancelmo J.D. | VP, General Counsel & Corporate Secretary |
| Mr. Peter W. Williams | Vice President of Human Resources |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | DEF 14A | e26114_omer-def14a.htm |
| 2026-03-31 | 8-K | omer20251116_8k.htm |
| 2026-03-31 | 10-K | omer20251231_10k.htm |
| 2026-01-07 | 8-K | omer20260107_8k.htm |
| 2025-12-29 | 8-K | omer20251218_8k.htm |
| 2025-12-01 | 8-K | omer20251024_8k.htm |
| 2025-11-13 | 8-K | omer20250825_8k.htm |
| 2025-10-15 | 8-K | omer20251014_8k.htm |
| 2025-08-14 | 8-K | omer20250521_8k.htm |
| 2025-08-14 | 10-Q | omer20250630_10q.htm |